Skip to main content

Sklamberg Quoted in Bloomberg Law on User Fee Reauthorization

September 16, 2022

Life Sciences & Healthcare Regulatory partner Howard Sklamberg was quoted in the Bloomberg Law article, “Tying FDA Fees to Stopgap Bill Seen as Missed Chance for Change.” The article discusses the growing tension between lawmakers and advocates as Senate health committee leaders try to add user fee reauthorization legislation to a bill before the fiscal year deadline, September 30. If user fee reauthorization is not reinstated, the FDA will suffer major cuts and layoffs.

Sklamberg stated that morale will also be impacted if user fee funding is not renewed, as it becomes harder for the FDA to do its job and the agency then “has to put together all sorts of contingency plans about how to staff things.”

» Read the full article (subscription required).